Taligen’s platform has the potential to lead the development of a new class of therapeutics that fight inflammatory, immune and other serious diseases through targeted delivery and local regulation of the natural power of complement system. Taligen’s novel approach is based upon building a drug discovery platform focused on targeted regulation of the undesirable complement system amplification that is known to be central to a number of diseases.

Natural pathway: Like other broad biotechnology platforms, Taligen’s selective complement regulator platform uses deep knowledge of the body’s own natural processes and specifically takes advantage of the complement system’s innate ability to recognize damaged tissues to direct powerful therapies to the sites of excessive inflammation.

Intelligent biologics: By allowing for selective regulation at key points in the complement system, Taligen’s platform enables the design of fusion proteins and monoclonal antibodies that stop disease-driven excessive inflammation before its initiation, while preserving the otherwise healthy immune system “surveillance” function.

Compelling benefits: Based on a deep understanding of complement biology coupled with novel technology, Taligen’s platform can enable the creation of therapeutics that are designed to be safe and effective because of their unique attributes:

• Selective intervention: Taligen is designing its therapeutics to regulate the complement system within the critical series of upstream biochemical reactions known as the complement amplification loop which is centrally responsible for initiating the excessive inflammatory response seen in an array of important inflammatory and immune diseases.
  
  
• Potent inflammation control: Many current anti-inflammatory agents target inflammation by attempting to systemically block single mediators far down in the inflammatory cascade, such as IL-4, IL-13, C5, and C5a. In contrast, Taligen precisely directs therapeutics to sites of local inflammation, resulting in concentrated regulation of many other downstream mediators and providing a completely new and potent approach to prevent the initiation of excessive inflammation.
  
  
• Targeted regulation: Taligen uses specific molecular structures of key naturally-occurring complement receptors to ensure that therapeutic modulators are delivered only to the cells where they are needed. Taligen and its founders have demonstrate that targeted delivery of molecules is possible using a specific chemical binding entity within the complement cascade known as complement receptor 2 (CR2).